Can the patient safely continue taking 1–2 tablets of diazepam (Valium) weekly for neck muscle spasm‑induced migraines and anxiety, given a history of medication reactions, while awaiting specialist evaluation, without developing dependence?

Yes, continuing 1–2 tablets of diazepam weekly for neck muscle spasm-related migraines and anxiety is reasonable until specialist evaluation, as this low-frequency use carries minimal addiction risk.

Risk Assessment for Dependence

At 1–2 tablets per week, your patient's risk of developing benzodiazepine dependence is very low. The FDA label for Valium clearly states that physical dependence develops from "continued therapy" and that withdrawal risk increases with "higher dosages" and "longer durations of use" 1. The critical threshold appears to be regular daily use over extended periods.

Key evidence on dependence risk:

• Duration matters most: A study of 180 patients found that continuous benzodiazepine treatment for less than 8 months resulted in only 5% withdrawal incidence, versus 43% for 8+ months of continuous use 2
• Intermittent use is fundamentally different: The patient is using 1–2 tablets weekly (approximately 2–4 days per month), which is far below the threshold for physical dependence
• Long-term intermittent use appears safe: A study of neurosurgical patients using diazepam for 1 month to 16 years for pain/muscle spasm found it retained efficacy without clear-cut abuse, with 83% reporting benefit 3

Clinical Context and Appropriateness

This intermittent use pattern for muscle spasm is actually within reasonable clinical practice, particularly given the patient's history of medication intolerances. The FDA label lists "adjunctively for relief of skeletal muscle spasm" as an approved indication at 2–10 mg, 3–4 times daily 1—your patient is using far less than this.

Important considerations:

• Neck muscle spasm is a recognized indication: One double-blind study demonstrated diazepam's statistically significant benefit for cervical muscle spasms compared to phenobarbital or placebo 4
• The medication intolerance history is relevant: Given past reactions to anxiety/migraine medications, having an effective option—even if not ideal long-term—provides important symptom control while awaiting specialist input
• Guideline context: The 2024 VA/DoD headache guideline identifies anxiolytic use as a risk factor for medication overuse headache when used frequently 5, but 1–2 tablets weekly does not constitute frequent use

Critical Warnings to Monitor

However, several important caveats must be addressed:

Avoid These High-Risk Scenarios:

1. No opioid co-administration: The FDA explicitly warns that combining benzodiazepines with opioids dramatically increases respiratory depression and mortality risk 1. If the patient requires opioids for any reason, this changes the risk-benefit calculation entirely

2. Watch for dose escalation: The primary concern is not current use but potential progression to daily use. Monitor that frequency remains at 1–2 tablets weekly, not per day

3. Medication overuse headache risk: While current use is low-frequency, the 2024 headache guideline identifies frequent anxiolytic use (≥7 days/month) as the highest risk factor for medication overuse headache 5. Your patient is currently at ~4–8 days/month, so this warrants monitoring

4. Benzodiazepines may paradoxically increase migraine risk: A 2017 population study found short-acting benzodiazepines (which includes diazepam's active metabolites) associated with increased migraine occurrence (OR 1.69) 6. This suggests benzodiazepines are not ideal for migraine management

Specific Recommendations Until Specialist Visit

Provide clear boundaries to the patient:

• Continue current frequency (1–2 tablets weekly maximum)
• Track actual usage in a diary to ensure frequency doesn't creep upward
• Avoid alcohol and other CNS depressants entirely when taking diazepam 1
• Do not drive or operate machinery on days when diazepam is taken, as psychomotor impairment persists even with chronic use 7
• If needing medication more than twice weekly, contact you before increasing frequency

Document the plan:

• This is bridge therapy pending specialist evaluation, not long-term management
• The specialist should evaluate alternative treatments for both muscle spasm (physical therapy, muscle relaxants without addiction potential) and migraine prevention (the guideline recommends candesartan, telmisartan, or CGRP antagonists as first-line preventives 5)

What the Specialist Should Consider

The specialist will likely want to address the underlying muscle spasm and migraine prophylaxis rather than continuing symptomatic benzodiazepine use. The 2024 guideline suggests insufficient evidence for benzodiazepines in headache management 5, and a Cochrane review found benzodiazepines ineffective for chronic musculoskeletal pain in rheumatoid arthritis with significant adverse events 8.

The current low-frequency use is acceptable as temporary management, but the goal should be transitioning to evidence-based preventive strategies that address the root cause rather than relying on intermittent benzodiazepine use.